Immunology Core
$270,000U19FY2022AINIH
Georgia State University, Atlanta GA
Investigators
Linked publications & trials
Paper 38864605Paper 38633880Paper 37517908Paper 37387605Paper 36321833Paper 36189345Paper 35862777Paper 35846739Paper 35480233Paper 35156850Paper 35102276Paper 34894134Paper 34396410Paper 34060328Paper 33464172Paper 33277359Paper 32457249Paper 32202529Paper 31681305Paper 31369630Paper 29760215Paper 29045638
Abstract
This Core component will take advantage of our established vaccine evaluation pipeline, which includes our innovative high throughput approaches facilitate our antigen engineering efforts by simultaneously allowing the reactivity of antiserum to be measured against all known antigenic variants of a given protein, and our humanized mouse-based infection models, which allow us to test the protective efficacy of vaccines during gonococcal asymptomatic colonization and disease. The results generated by this Core are central to vaccine design and formulation efforts being undertaken in Projects 1 and 2, and will be used to inform the vaccine impact modeling being performed in Project 3.
View original record on NIH RePORTER →